Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

mpact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact

Teva:
Teva Pharmaceutical Industries Ltd.
Dan Suesskind, Chief Financial Officer
+ 972 2 589 28 40
or
Teva North America
George Barrett, President and CEO
+1 215 591 30 30
or
Teva Investor Relations
Liraz Kalif / Kevin Mannix
+972 3 926 72 81 / +1 215 591 89 12
or
Active Biotech:
Sven Andréasson, President & CEO
+46 46 19 20 49
Tomas Leander
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:9/29/2014)... SAN DIEGO , 29. ... Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) und ... gaben heute gemeinsam eine definitive Fusionsvereinbarung bekannt, ... von Ambit Biosciences für 15 US-Dollar je ... anschließenden Zusammenschluss mit einem Tochterunternehmen von Daiichi ...
(Date:9/29/2014)... IRVING, Texas , Sept. 29, 2014 /PRNewswire/ ... 340B Drug Pricing Program, has announced that it ... Services Administration (HRSA) to continue serving in its ... 2019. Apexus, which has held this position for ... with more than 25,000 safety-net provider locations, drug ...
(Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
... Medical Inc. (TMI),announced today that it has been ... commercialize in Europe the Antares(TM) Coronary,Stent System, a ... use,at or near coronary bifurcations., Representing the ... potential use in a quarter of the 2.2 ...
... Line Clinical Results Expected in November 2008, BOTHELL, ... ) announced today the completion of patient enrollment and ... evaluate the safety and,efficacy of its formulation of 12-hour ... expects to report top-line,results from this pivotal trial in ...
Cached Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3
(Date:9/30/2014)... KY (PRWEB) September 30, 2014 Up ... people in the United States alone have sleep apnea. ... and of those treated, many cannot tolerate their prescribed ... supplied through a nasal mask) – which supports the ... night’s sleep has become especially valuable, and increasingly difficult ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take ... p.m. at the Youth Town campus (3641 Youth Town ... family-oriented festival, which will offer music, food and games. ... car show, arts and crafts fair, music, championship barbeque ... Lightning McQueen and Mater from the hit Disney movie ...
(Date:9/30/2014)... September 30, 2014 Top10inaction.com, one of ... on ranking and reviewing all essential categories in daily ... announced the best liquid foundation at http://top10inaction.com/liquid-foundations/ , ... is named as the best foundation of them all. ... well as high end brands, hence customers have more ...
(Date:9/30/2014)... September 30, 2014 3M has added four ... high bond tapes. 3M 5906 , 3M 5907 ... are conformable VHBs which help create the strongest bond possible ... are used for bonding to difficult surfaces such as paints, ... 5906, 5907, 5908, and 5905 are designed specifically for electronic ...
Breaking Medicine News(10 mins):Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3
... The University of Pittsburgh Cancer Institute (UPCI) today ... F. Shapira BRCA Cancer Research Program. BRCA 1 and ... the risk of breast, prostate, ovarian and pancreatic cancers. ... this research program to UPCI, said Ronald Herberman, M.D., ...
... people on trial were granted the right to an interpreter ... by UCL (University College London) scientists. The use of family ... teachers and eventually written testimony, which may have disadvantaged the ... British Sign Language was emerging. , The study, ...
... debt and expands available credit facility, HATBORO, ... leading technology provider of enterprise mobility solutions for,the ... has,completed a senior debt financing of up to ... HTGC )., (Logo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH165LOGO ...
... country and online offer opportunity to save a life, ... of adding,46,000 new members to the marrow Registry during ... Marrow Donor Program,s largest,annual awareness campaign, kicks off today., ... other,life-threatening diseases, a marrow transplant offers a second chance ...
... and atypical cells also indicate high risk of second cancer, study ... have been diagnosed with breast cancer, having a known mutation in ... second cancer, and many of these women choose to have their ... However, new research suggests that women who don,t have ...
... May 5 Facet Solutions, Inc., a privately,held ... announced the successful completion of a scientific,evaluation for ... The study,evaluated the combination of Facet Solutions, Anatomic ... device in a,finite element model. The details of ...
Cached Medicine News:Health News:Research program focuses on genetic mutations and cancer risk 2Health News:'Deaf by God' tried in Old Bailey records 2Health News:'Deaf by God' tried in Old Bailey records 3Health News:InfoLogix Completes $25 Million Senior Debt Financing 2Health News:InfoLogix Completes $25 Million Senior Debt Financing 3Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 2Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 3Health News:BRCA Mutations Don't Spot All High-Risk Women 2Health News:BRCA Mutations Don't Spot All High-Risk Women 3Health News:Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study 2
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 3 mm x 1.0 mm x 3.0 mm....
Medicine Products: